Patents Examined by Amy H. Bowman
  • Patent number: 10478500
    Abstract: The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and method of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: November 19, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: William Querbes, Kevin Fitzgerald, Brian Bettencourt, Abigail Liebow, David V. Erbe
  • Patent number: 10472625
    Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: November 12, 2019
    Assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
    Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
  • Patent number: 10472628
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 12, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • Patent number: 10457943
    Abstract: The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 29, 2019
    Assignee: Andes Biotechnologies Global Inc.
    Inventors: Luis O. Burzio Eriz, Veronica A. Burzio Menendez, Jaime E. Villegas Olavarria
  • Patent number: 10457941
    Abstract: Methods and compounds useful to treat diseases and conditions are provided. Methods of administering one or more microRNA-inhibitor compounds or one or more microRNA-enhancing compounds to cells, tissues, and/or subjects as a treatment for a disease or condition are provided.
    Type: Grant
    Filed: August 20, 2016
    Date of Patent: October 29, 2019
    Assignee: Asociacion Centro de Investigacion Cooperativa en Biociencias-CIC bioGUNE
    Inventors: Maria Luz Martinez Chantar, Juan Anguita
  • Patent number: 10450572
    Abstract: This document relates to materials and methods for treating cancer (e.g., prostate cancer). For example, methods for using one or more androgen receptor variant (AR-V) inhibitors (e.g., morpholinos) to treat a mammal having prostate cancer (e.g., castration-resistant prostate cancer) are provided.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 22, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Jamie Lynn Van Etten, Scott M. Dehm
  • Patent number: 10443058
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 15, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Patent number: 10441546
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: October 15, 2019
    Assignee: EnGenelC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 10434117
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: October 8, 2019
    Assignee: Julius-Maximilians-Universitat Wurzburg
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
  • Patent number: 10426736
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 1, 2019
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY. LTD.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10420723
    Abstract: A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: September 24, 2019
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Ramesh C. Gupta, Radha Munagala, Farrukh Aqil, Jeyaprakash Jeyabalan
  • Patent number: 10405539
    Abstract: In one aspect, the present invention relates to a composition for delivery of double stranded RNA to an insect having a basic pH within its alimentary canal, wherein the composition comprises double stranded RNA adsorbed onto a clay complex, and wherein the clay complex is configured to release the double stranded RNA at the basic pH. Other aspects of the invention relate to preparations including the composition of the invention, methods of delivering double stranded RNA to an insect and methods of protecting a crop against an insect.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: September 10, 2019
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Neena Mitter, Zhi Ping Xu
  • Patent number: 10392621
    Abstract: Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: August 27, 2019
    Assignee: SomaLogic, Inc.
    Inventors: Urs A. Ochsner, Louis S. Green, Larry Gold, Nebojsa Janjic
  • Patent number: 10385342
    Abstract: The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 20, 2019
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Nanna Albæk, Maj Hedtjärn, Marie Wickstrom Lindholm, Niels Fisker Nielsen, Andreas Petri, Jacob Ravn
  • Patent number: 10383935
    Abstract: This disclosure provides live, attenuated viruses, and methods of making and using the live, attenuated viruses.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: August 20, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Ryan Andrew Langlois, Jessica Karen Fiege, Louisa Elizabeth Sjaastad, Barbara Mae Waring
  • Patent number: 10383827
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 20, 2019
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 10385338
    Abstract: The present invention relates to nucleic acids, compositions and methods for the treatment of facioscapulohumeral dystrophy.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: August 20, 2019
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Julie Dumonceaux, Thomas Voit, Virginie Mariot
  • Patent number: 10378015
    Abstract: Described herein are methods of identifying host factors that modulate Hepatitis B virus (HBV) replication in mammalian, e.g., human cells, as well as factors identified by those methods, and methods of treating HBV infections by targeting those factors. Zinc finger, CCHC domain containing 14 (ZCCHC14) is an exemplary host factor.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 13, 2019
    Assignee: University of Massachusetts
    Inventors: Abraham L. Brass, Miles C. Smith
  • Patent number: 10376535
    Abstract: Provided herein, inter alia, are methods and compositions directed to suppressing tumor cell growth in a subject as well as methods for sensitizing a proliferating cell for treatment with a cytotoxic agent via inhibiting expression of HE4 and one or more immune checkpoint inhibitors (ICIs). Also provided herein are methods for determining whether a subject who has been diagnosed with cancer would benefit from immunotherapy as well as methods for determining whether a subject with cancer is responding to immunotherapy via assessment of levels of HE4 gene and/or protein expression.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: August 13, 2019
    Assignee: University of Rochester
    Inventors: Richard G. Moore, Rakesh K. Singh, Naohiro Yano
  • Patent number: 10370722
    Abstract: This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: August 6, 2019
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei Kawauchi, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Hiroko Sudo, Atsushi Ochiai, Motohiro Kojima